Amifer Junior

Form: Syrup
Packaging: Bottle 150 ml

Active substance:  Elemental iron

Form: Suspension -Syrup

Dosage: 50mg Iron/5ml


  • Bottle 150 ml
  • Plastic dosing spoon (indications 1,25 ml- 2,5 ml -5 ml).


Target: AMIFER® Junior is a medicine for the treatment of neonates and children; it can also be used in adults.

Amifer Junior is used to prevent and correct iron deficiency before and during the stage of iron deficiency anemia. AMIFER® Junior is a medicine for the treatment of newborns and children; however, it can also be used in adults.

Recommended dosage in children is 2 mg iron/kg/day.

  • Infants and children (6 months – 2 years):

1/4 spoon (= 1.25 ml) once a day (= 12.5 mg of iron).

  • Children (2 – 5 years):

1/2 spoon (= 2.5 ml) 1 – 2 times a day (= 25 – 50 mg of iron).

  • Children (6 -12 years):

1 spoon (= 5 ml) 1 – 2 times a day (= 50 – 100 mg of iron).

  • Adolescents, adults and elderly:

1 spoon (= 5 ml) 2 times a day (= 100 mg of iron).


AMIFER Junior must be taken with or after meals, it may be taken by mixing with fruit or vegetable juices; not with milk (iron formulations must be taken at least 2 hours after milk or calcium products).

Over-the-counter drug

Notice of Trademark Infringement

Dear valued partners, customers and Dafra representatives,

It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo ( In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.

Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.

We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.

We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.

As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.

Thank you for your continued support and trust in our company.

Dafra Pharma